Riskpilot← Back to searchSign inGet full accessKripthonite Therapeutics ApS
APSActiveCVR 43770209Palle Juul-Jensens Boulevard 82Manufacture of pharmaceutical preparations · NACE 2120Est. 20234 employees
Revenue 2025
DKK -3,5M
-2900% vs 2024
EBITDA margin
140.7%
Equity ratio
95.9%
Financial strength
Net profit 2025
DKK -3,9M
-12300756% vs 2024
| Revenue | DKK -3,5M | -2900% |
| EBITDA | DKK -4,9M | — |
| Net profit | DKK -3,9M | -12300756% |
| Total assets | DKK 4,8M | +2745% |
| Equity | DKK 4,6M | +13205% |
| Employees | 4 | — |
Legal name
Kripthonite Therapeutics ApS
CVR number
43770209
Legal form
Anpartsselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
10. januar 2023
Share capital
DKK 47.813
Employees
4 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af to bestyrelsesmedlemmer i forening.
Company purpose
Selskabets formål er forskning og udvikling af lægemidler og dermed beslægtet virksomhed.
Address
Palle Juul-Jensens Boulevard 82
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 542 | 125 | -3.513 |
| Staff expenses | -546 | -125 | -1.431 |
| EBITDA | -5 | 0 | -4.944 |
| Depreciation & amort. | -0 | -0 | -0 |
| EBIT | -5 | 0 | -4.944 |
| Net financials | -1 | -0 | -24 |
| Profit before tax | -5 | -0 | -4.967 |
| Tax | -0 | -0 | -1.031 |
| Net profit | -5 | -0 | -3.936 |
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total assets | 75 | 169 | 4.793 |
| Equity | 35 | 35 | 4.598 |
| Long-term debt | 0 | 0 | 0 |
| Short-term debt | 41 | 134 | 195 |
| Total debt | 41 | 134 | 195 |
EBITDA margin
-494359000.0%
This company
15.8%
Market median
-3128854530% vs market
20232025
Equity ratio
95.9%
This company
38.2%
Market median
+151% vs market
20232025
Return on equity
-85.6%
This company
18.4%
Market median
-565% vs market
20232025
Net profit margin
-393627400.0%
This company
8.1%
Market median
-4859597631% vs market
20232025
Asset turnover
-0.73×
This company
1.12×
Market median
-165% vs market
20232025
Debt / equity
0.04×
This company
0.62×
Market median
+94% vs market
20232025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-10 – 2023-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JS Management | Management | 2026 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2025 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2026 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Thomas B. Poulsen Holding ApS | Company | 20.0% | 20.0% | 2025 |
Hjerrild Chemistry Consulting ApS | Company | 20.0% | 20.0% | 2025 |
Jacobsen Biotech ApS | Company | 20.0% | 20.0% | 2025 |
Marigold Innovation ApS | Company | 20.0% | 20.0% | 2025 |
Marigold Maturation Fund K/S | Company | 15.0% | 15.0% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
MIJJB Holding ApS
Kripthonite Therapeutics ApS Board members of Kripthonite Therapeutics ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jan Stenvang | Management | 0 companies |
| Søren Bregenholt Frederiksen | Chairman | 0 companies |
| Kristian Mark Jacobsen | Board of Directors | 0 companies |
| Per Hjerrild | Board of Directors | 0 companies |
| Peter Horn Møller | Chairman | 0 companies |
| Thomas Bjørnskov Poulsen | Board of Directors | 0 companies |
| Erik Vinther | Board of Directors | 0 companies |